Method of detecting adenoma
AssigneesVision Tech Bio Pty Ltd, Commonwealth Scientific and Industrial Research Organisation
InventorsTrevor LOCKETT, Michael BUCKLEY, Craig LEWIS, Christian DAISH, Louise FORMBY-MILLER, Leah COSGROVE, Kim Yoke Ching FUNG, Ilka PRIEBE
Life of this patent
Estimating the term…
Abstract
The disclose relates to adenomas of the colon. More particularly, the present disclosure relates to biomarkers which may be used for the detection of advanced colorectal pre-cancerous adenomas (APA) The detection and measurement of these biomarkers in a biological sample may be used to inform the clinician as to whether further invasive procedures such as polypectomy are required.
Claims45
A method for the detection of colorectal pre-cancerous adenomas (APA) in a subject, the method comprising:
- determining a measurement for a panel of biomarkers in a biological sample obtained from the subject, the panel comprising
- at least IGFBP2 and one or more further biomarkers selected from the group consisting of DKK-3, tumour M2PK, Mac2BP, TGFβ1, TIMP1, IL-8, IL-13 and EpCAM;
- and
- optionally BDNF
- wherein the measurement comprises measuring a level of each of the biomarkers in the panel.
A method for the detection of pre-cancerous colorectal adenomas in a subject, the method comprising:
- determining a measurement for a panel of biomarkers in a biological sample obtained from the subject, the panel comprising:
- at least IGFBP2 and the subject's age as a biomarker and one or more further biomarkers selected from the group consisting of DKK-3, tumour M2PK, Mac2BP, TGFβ1, TIMP1, IL-8, IL-13 and EpCAM;
- and
- optionally BDNF;
- wherein the measurement comprises measuring a level of each of the biomarkers in the panel.
A method for the detection of pre-cancerous colorectal adenomas in a subject, the method comprising:
- determining a measurement for a panel of biomarkers in a biological sample obtained from the subject, the panel comprising:
- at least IGFBP2 and the subject's gender as a biomarker and one or more further biomarkers selected from the group consisting of DKK-3, tumour M2PK, Mac2BP, TGFβ1, TIMP1, IL-8, IL-13 and EpCAM;
- and
- optionally BDNF,
- wherein the measurement comprises measuring a level of each of the biomarkers in the panel.
The method according to any preceding claim, wherein determining a measurement comprises detecting biomarkers in the biological sample by contacting the sample with detectable binding agents that specifically bind to the biomarkers.
The method according to any preceding claim, wherein determining a measurement comprises measuring the concentration of biomarker in the biological sample.
The method according to any preceding claim, wherein determining a measurement comprises performing a statistical analysis.
The method according to any preceding claim, wherein the biomarkers are protein biomarkers.
The method according to any preceding claim, wherein the biological sample is whole blood, plasma or serum.
Dependencies are inferred from the claim text.